Business
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
PONTE VEDRA, Fla., May 08, 2025--Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
About this update from Cadrenal Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2289,"height":530,"url":"https://media.zenfs.com/en/business-wire.com/8668a85d940902cb987ac33f9935fcd6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/80yTMtjBpckBT0qON7Cgdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8668a85d940902cb987ac33f9935fcd6","width":960,"height":222},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/FtC0Baa9.kA9GR74Mrzg5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/8668a85d940902cb987ac33f9935fcd6","width":1200,"height":278}},"lazy":false},{"type":"text","content":"Leadership appointment strengthens strategic and development capabilities","length":73,"tagName":"p","attribs":{}},{"type":"text","content":"FDA Type D Meeting provides additional guidance for advancing the clinical development of tecarfarin","length":100,"tagName":"p","attribs":{}},{"type":"text","content":"Collaboration Agreement with Abbott (NYSE: ABT) validates the need for new anticoagulation options","length":98,"tagName":"p","attribs":{}},{"type":"text","content":"PONTE VEDRA, Fla., May 08, 2025--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on the strategic focus of the company and clinical development of tecarfarin.","length":369,"tagName":"p"},{"type":"text","content":""In the first quarter of 2025, Cadrenal continued to build on the momentum we achieved during 2024," said Quang X. Pham, Chairman & CEO. "The appointment of James Ferguson, M.D., FACC, FAHA, as our Chief Medical Officer positions us for success in reviewing potential assets to add to our portfolio and designing and executing our clinical program for tecarfarin. The finalized Collaboration Agreement with Abbott validates the critical need in the market for a new anticoagulant for patients with left ventricular assist devices (LVADs). And our meeting with the FDA provided additional guidance in the design of a pivotal trial."","length":655,"tagName":"p"},{"type":"text","content":"Highlights fro...